Novartis AG (NYSE:NVS) Shares Bought by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. grew its position in shares of Novartis AG (NYSE:NVS) by 12.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 6,171 shares of the company’s stock after purchasing an additional 679 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novartis were worth $600,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new position in shares of Novartis during the 3rd quarter valued at $28,000. Richardson Financial Services Inc. acquired a new position in shares of Novartis during the 2nd quarter valued at $30,000. Fortitude Family Office LLC increased its position in shares of Novartis by 503.8% during the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after purchasing an additional 267 shares during the period. Clean Yield Group acquired a new position in shares of Novartis during the 3rd quarter valued at $43,000. Finally, Beaird Harris Wealth Management LLC increased its position in shares of Novartis by 280.5% during the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock valued at $81,000 after purchasing an additional 519 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVS. BMO Capital Markets lifted their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Erste Group Bank restated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Performance

Shares of NVS stock opened at $99.06 on Friday. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $202.48 billion, a price-to-earnings ratio of 11.51, a P/E/G ratio of 1.49 and a beta of 0.57. The stock’s fifty day simple moving average is $101.55 and its 200-day simple moving average is $109.26.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the company posted $1.74 earnings per share. On average, sell-side analysts predict that Novartis AG will post 7.65 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.